/
Cardiovascular
Cardiomyopathy
51
Pipeline Programs↗
124
Active Trials↗
26
Companies Involved↗
Cardiomyopathy is a moderately active landscape with 51 programs across 26 companies. The most active players are Alnylam Pharmaceuticals, Applied Therapeutics, Inc., Intellia Therapeutics. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 13
Phase 29
Phase 316
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
42 of 45 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.
Analysis
Trial Status
293
clinical trials
Completed104 · 35%
Recruiting76 · 26%
Unknown status32 · 11%
Active, not recruiting28 · 10%
Terminated21 · 7%
Not yet recruiting17 · 6%
Other15 · 5%
Clinical Trials
Trial Activity
293 trials
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)